First experience of concomitant vaccination against dengue and MMR in toddlers

Pediatric Infectious Disease Journal

Volumn 34, Issue 8, 2015, Pages 884-892

  Crevat, Denis ^a   Brion, Job D ^b   Gailhardou, Sophia ^a   Laot, Thelma M ^c   Capeding, Maria Rosario ^d  

^a SANOFI PASTEUR   (France)

^b San Pablo City Health Office   (United States)

^c Sanofi Pasteur   (Philippines)

^d RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

Author keywords

immunogenicity; reactogenicity; safety; vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; CHICKENPOX VACCINE; DENGUE VACCINE; HEPATITIS A VACCINE; MEASLES MUMPS RUBELLA VACCINE; PLACEBO; BACTERIUM ANTIBODY; VIRUS ANTIBODY;

ACUTE GASTROENTERITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DENGUE; DESCRIPTIVE RESEARCH; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIENCE; FEBRILE CONVULSION; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATHOLOGICAL CRYING; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SERODIAGNOSIS; SIDE EFFECT; SYSTEMIC DISEASE; TODDLER; TREATMENT RESPONSE; VACCINATION; VACCINATION REACTION; VIRUS LOAD; VIRUS NEUTRALIZATION; VOMITING; BLOOD; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; INFANT; VIREMIA;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; VIREMIA;

EID: 84937392478     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000752     Document Type: Article

References (28)

1. Halstead SB. Dengue. Lancet. 2007; 370: 1644-1652
2. WHO. Global strategy for dengue prevention and control 2012-2020, 2012: 1-43. Available from: http://apps.who.int/iris/bitstream/10665/75303/1/9789241504034-eng.pdf. Accessed July 4, 2010
3. WHO. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. 2nd edition. Geneva: World Health Organization; 1997. Available from: http://apps.who.int/iris/bitstream/10665/41988/1/9241545003-eng. pdf. Accessed 4 July 2013
4. Gubler DJ, Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res. 1999; 53: 35-70
5. Health PDo. Disease Surveillance Report. Available from: http://www.doh. gov.ph/sites/default/files/2012Den28WMR.pdf. Accessed July 14, 2012
6. Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012; 8: 1259-1271
7. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012; 380: 1559-1567
8. Poo J, Galan F, Forrat R, et al. Live-Attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediat Infect Dis J. 2011; 30: e9-e17
9. Morrison D, Legg TJ, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010; 201: 370-377
10. Lanata CF, Andrade T, Gil AI, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012; 30: 5935-5941
11. Capeding RZ, Luna IA, Bomasang E, et al. Live-Attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011; 29: 3863-3872
12. Tran NH, Luong CQ, Vu TQH, et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 2012; 3: 162
13. Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372: 113-123
14. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384: 1358-1365
15. Van Panhuis WG, Luxemburger C, Pengsaa K, et al. Decay and persistence of maternal dengue antibodies among infants in Bangkok. Am J Trop Med Hyg. 2011; 85: 355-362
16. UNICEF. Immunization Summary. A statistical Reference Containing Data Through 2011; 2012. Available from: http://www.childinfo.org/files/immunization- summary-2012-en.pdf. Accessed July 4, 2013
17. Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012; 31: e24-e30
18. Mantel N, Aguirre M, Gulia S, et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods. 2008; 151: 40-46
19. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008; 21: 123-132
20. Timiryasova TM, Bonaparte MI, Luo P, et al. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg. 2013; 88: 962-970
21. Verbeek NE, Jansen FE, Vermeer-de Bondt PE, et al. Etiologies for seizures around the time of vaccination. Pediatrics. 2014; 134: 658-666
22. Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013; 167: 1111-1117
23. Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Human Vaccines. 2010; 6: 696-705
24. Nascimento Silva JR, Camacho LA, Siqueira MM, et al.; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011; 29: 6327-6334
25. Huang LM, Lin TY, Chiu CH, et al. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine. 2014; 32: 5363-5369
26. Usonis V, Bakasenas V, Kaufhold A, et al. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J. 1999; 18: 42-48
27. Shinefield HR, Black SB, Staehle BO, et al; Kaiser Permanente Medical Team for Varivax. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002; 21: 555-561
28. Rinderknecht S, Michaels MG, Blatter M, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measlesmumps- rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011; 30: e179-e185